Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials

John B. Buse; Alan Garber; Julio Rosenstock; Wolfgang E. Schmidt; Jason H. Brett; Nicoline Videb?k; Jens Holst; Michael Nauck

首页> 外文期刊>The journal of clinical endocrinology and metabolism >Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials

【24h】

Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials

机译：利拉鲁肽的治疗与抗体形成的频率低和幅度大有关，对血糖反应或不良事件的发生频率没有明显影响：利拉鲁肽在糖尿病（LEAD）试验中的作用和作用的结果

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Context:Therapeutic proteins/peptides can produce immunogenic responses that may increase the risk of adverse events or reduce efficacy.

机译：背景：治疗性蛋白质/肽可能产生免疫原性应答，可能会增加不良事件的风险或降低疗效。

著录项

来源
《The journal of clinical endocrinology and metabolism》 |2011年第6期|共8页
作者
John B. Buse; Alan Garber; Julio Rosenstock; Wolfgang E. Schmidt; Jason H. Brett; Nicoline Videb?k; Jens Holst; Michael Nauck;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类代谢病;
关键词

相似文献

外文文献
中文文献
专利

1. Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials [J] . John B. Buse, Alan Garber, Julio Rosenstock, The journal of clinical endocrinology and metabolism . 2011,第6期

机译：利拉鲁肽的治疗与抗体形成的频率低和幅度大有关，对血糖反应或不良事件的发生频率没有明显影响：利拉鲁肽在糖尿病（LEAD）试验中的作用和作用的结果
2. Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. [J] . Madsbad S, Schmitz O, Ranstam J, Diabetes care . 2004,第6期

机译：使用长效胰高血糖素样肽1类似物利拉鲁肽（NN2211）进行每日一次治疗后，改善了2型糖尿病患者的血糖控制，且体重没有增加：这项为期12周的双盲，随机，对照试验。
3. Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920 [J] . Nauck Michael A., Kreiner Eskil, Rasmussen Soren, Diabetes care . 2020,第2期

机译：对Nauck等人评论的回应。 Liraglutide与安慰剂对患有2型糖尿病患者患者的患者患者的影响，在患有2型糖尿病患者中的心血管事件中的患者随机试验。 2019年糖尿病护理; 42：1912-1920
4. LOW MAGNITUDE AND HIGH FREQUENCY VIBRATION PREVENTS SIMULATED MICROGRAVITY-INDUCED DECREASE IN A BONE FORMATION RESPONSE IN OSTEOBLASTS [C] . Mamta Patel, Roger Talish, Clinton Rubin, International Astronautical Congress(IAC2006); 20061002-06; Valencia(ES) . 2006

机译：骨母细胞骨形成反应中微重力引起的低幅度振动和高频振动预防
5. Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920 [O] . Michael A. Nauck, Eskil Kreiner, Søren Rasmussen, 2020

机译：对Nauck等人评论的回应。 Liraglutide与安慰剂对患有2型糖尿病患者患者的患者患者的影响在患有2型糖尿病患者中的心血管事件中的患者随机试验。 2019年糖尿病护理; 42：1912-1920
6. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events : results from the Liraglutide Effect and Action in Diabetes (LEAD) trials [O] . Buse, John, Garber, Alan, Rosenstock, Julio, 2011

机译：利拉鲁肽治疗与抗体形成的频率低和强度相关，对血糖反应或不良事件发生频率没有明显影响：利拉鲁肽在糖尿病中的作用和作用（LEAD）试验的结果

Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials

摘要

著录项

相似文献

相关主题

期刊订阅